Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Savior LifetecROCO:4167 -1.31%70 EV-to-EBITDA is 3.40 as of Sep. 08, 2026, which is 83% below its 10-year median of 19.93. GuruFocus rates ROCO:4167 with a GF Score™ of 70/100 and a GF Value™ of NT$18.24 (Fairly Valued). The stock has 6 warning signs investors should review. Among 399 Biotechnology companies, Savior Lifetec ranks better than 72.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Savior Lifetec's enterprise value is NT$3,836 Mil.
Savior Lifetec's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1,130 Mil. Therefore, Savior Lifetec's EV-to-EBITDA for today is 3.40.
The historical rank and industry rank for Savior Lifetec's EV-to-EBITDA or its related term are showing as below:
ROCO:4167'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -246.62 Med: 19.93 Max: 192.2
Current: 3.4
During the past 13 years, the highest EV-to-EBITDA of Savior Lifetec was 192.20. The lowest was -246.62. And the median was 19.93.
ROCO:4167's EV-to-EBITDA is ranked better than 72.43% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs ROCO:4167: 3.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Savior Lifetec's PE Ratio (TTM) for today is calculated as:
Savior Lifetec's share price for today is NT$18.90.
Savior Lifetec's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.949.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Savior Lifetec's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4167 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Savior Lifetec's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Savior Lifetec EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Savior Lifetec's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Savior Lifetec's EV-to-EBITDA falls into.
Savior Lifetec's current Enterprise Value is NT$3,836 Mil.
Savior Lifetec's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,130 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Savior Lifetec (ROCO:4167) has a EV-to-EBITDA of 3.40 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Savior Lifetec. This is 83% below median its historical median of 19.93. According to the industry distribution chart, Savior Lifetec ranks #110 out of 399 companies in the Biotechnology industry, placing it in the top 27.6%.
Is Savior Lifetec's EV-to-EBITDA too high?
Savior Lifetec's current EV-to-EBITDA of 3.40 is 83% below median its 10-year median of 19.93. The Biotechnology industry median EV-to-EBITDA is 13.70. Savior Lifetec's value of 3.40 is 75.2% below this industry median. Based on the distribution chart, Savior Lifetec ranks #110 out of 399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Savior Lifetec has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Savior Lifetec's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Savior Lifetec ranks #110 out of 399 companies for EV-to-EBITDA. This puts Savior Lifetec in the upper half of its industry. The industry median EV-to-EBITDA is 13.70. Savior Lifetec's value of 3.40 is 75.2% below this benchmark. While the company's 10-year median is 19.93 vs. the industry median of 13.70, Savior Lifetec has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Savior Lifetec's current EV-to-EBITDA of 3.40 is 75.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Savior Lifetec. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Savior Lifetec's current EV-to-EBITDA is 3.40, which is 83% below median its own 10-year median of 19.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Savior Lifetec stock overvalued right now?
Based on GuruFocus' analysis, Savior Lifetec (ROCO:4167) is currently considered Fairly Valued. The stock's GF Value™ is NT$18.24, compared to a current price of NT$18.90 — trading 3.6% above its estimated fair value. The current EV-to-EBITDA is 3.40, which is 83% below median its 10-year median of 19.93 and 75.2% below the Biotechnology industry median of 13.70. Savior Lifetec's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Savior Lifetec (ROCO:4167), the current EV-to-EBITDA is 3.40 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Savior Lifetec (ROCO:4167) Overvalued in 2026?
Based on GuruFocus' analysis, Savior Lifetec stock appears to be overvalued.
The current stock price of NT$18.90 is trading 3.6% above its estimated GF Value™ of NT$18.24.
GuruFocus considers Savior Lifetec to be Fairly Valued.
Key valuation signals for ROCO:4167:
EV-to-EBITDA: 3.40 (83% below median its 10-year median of 19.93)
GF Value™: NT$18.24 vs. price of NT$18.90 (3.6% above fair value)
Industry Position: 75.2% below the Biotechnology median (#110 of 399)
No single metric tells the full story. See the ROCO:4167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Savior Lifetec Corp is engaged in the research, development, design, manufacture, and sale of carbapenem generics, injection generics, controlled-release generics, development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms of the aforementioned products. The company also provides medicine manufacturer technology and services. The company geographically operates in four regions: the Americas, Asia, Taiwan, and Europe.
70GF Score
Get the complete analysis for ROCO:4167
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4167 has been successfully added to your 
